Original articlePredictors of Long-term Progression in the Early Manifest Glaucoma Trial
Section snippets
Materials and Methods
As detailed in previous reports,1, 2, 3 the trial included 255 men and women, 50 to 80 years of age with newly diagnosed and untreated glaucoma with early visual field defects, mainly recruited through population screening. Patients were randomized to treatment with betaxolol plus argon laser trabeculoplasty or no immediate treatment (129 treated and 126 controls) and followed every 3 months. The National Eye Institute and the Swedish Research Council funded the study.
Results
At the close of the study, 67% of the patients had progressed. The median time to progression was 60 months and the median follow-up time was 8 years. Table 1 presents univariate HR and median time to progression for significant factors. Progression was 59% in treated versus 76% in control patients, for an unadjusted HR of 0.60. This HR is of the same magnitude as that previously reported,2 which was based on a shorter follow-up and a lower progression of 53% (45% among treated and 62% among
Discussion
The updated results of EMGT reveal stability of previously reported estimates, confirming the important effect of treatment on progression, as well as of IOP, exfoliation, bilateral disease, and older age.2 The current analyses, based on a longer follow-up period, showed only minor variations in HR for these baseline and follow-up progression factors (Table 2). However, the extended follow-up with additional progressions at the end of the study allowed identifying new significant predictors.
References (36)
- et al.
Early Manifest Glaucoma Trial: design and baseline data
Ophthalmology
(1999) - et al.
Risk of glaucoma in ocular hypertension with and without pseudoexfoliation
Ophthalmology
(2005) - et al.
The impact of ocular blood flow in glaucoma
Prog Retin Eye Res
(2002) - et al.
Autonomic nervous system, circadian rhythms, and primary open-angle glaucoma
Surv Ophthalmol
(2004) - et al.
Vascular risk factors for primary open angle glaucoma: the Egna-Neumarkt Study
Ophthalmology
(2000) - et al.
Primary open-angle glaucoma, intraocular pressure, and systemic blood pressure in the general elderly population: the Rotterdam Study
Ophthalmology
(1995) - et al.
A sick eye in a sick body?Systemic findings in patients with primary open-angle glaucoma
Surv Ophthalmol
(2006) - et al.
Nocturnal arterial hypotension and its role in optic nerve head and ocular ischemic disorders
Am J Ophthalmol
(1994) - et al.
Optic nerve blood flow in glaucoma: effect of systemic hypertension
Am J Ophthalmol
(1999) - et al.
Corneal thickness as a risk factor for visual field loss in patients with preperimetric glaucomatous optic neuropathy
Am J Ophthalmol
(2003)
Central corneal pachymetry and visual field progression in patients with open-angle glaucoma
Ophthalmology
Central corneal thickness and corneal hysteresis associated with glaucoma damage
Am J Ophthalmol
Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial
Arch Ophthalmol
Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial
Arch Ophthalmol
Perimetric probability maps to separate change caused by glaucoma from that caused by cataract
Acta Ophthalmol Scand
Regression models and life-tables
J R Stat Soc Ser B
Covariance analysis of censored survival data
Biometrics
Survival Analysis Using SAS: A Practical Guide
Cited by (1093)
Addressing neurodegeneration in glaucoma: Mechanisms, challenges, and treatments
2024, Progress in Retinal and Eye ResearchNeurovascular dysfunction in glaucoma
2023, Progress in Retinal and Eye ResearchAssociation of Postural Blood Pressure Response With Disease Severity in Primary Open Angle Glaucoma
2024, Journal of Glaucoma
Manuscript no. 2006-1164.
The authors have no commercial or proprietary interest in the products or companies mentioned in the article.
- ⁎
Members also include the Department of Ophthalmology, Lund University Hospital, Lund, Sweden; Department of Ophthalmology, Helsingborg Hospital, Helsingborg, Sweden; and National Eye Institute, National Institutes of Health, Bethesda, Maryland.